Genio® System
Moderate to Severe Obstructive Sleep Apnea (CPAP failures)
Key Facts
About Nyxoah
Nyxoah's mission is to address the significant unmet needs in Obstructive Sleep Apnea (OSA) treatment by moving beyond the low-compliance standard of CPAP therapy. Its key achievement is the development and regulatory approval of the innovative Genio® neurostimulation system, which features a unique leadless, battery-free design activated by an external patch. The company's strategy is to drive global commercialization of Genio®, expand its clinical evidence base, and pursue label expansions to treat a broader patient population, positioning itself as a leader in the OSA neurostimulation market.
View full company profileAbout Nyxoah
Nyxoah's mission is to address the significant unmet needs in Obstructive Sleep Apnea (OSA) treatment by moving beyond the low-compliance standard of CPAP therapy. Its key achievement is the development and regulatory approval of the innovative Genio® neurostimulation system, which features a unique leadless, battery-free design activated by an external patch. The company's strategy is to drive global commercialization of Genio®, expand its clinical evidence base, and pursue label expansions to treat a broader patient population, positioning itself as a leader in the OSA neurostimulation market.
View full company profileAbout Nyxoah
Nyxoah's mission is to address the significant unmet needs in Obstructive Sleep Apnea (OSA) treatment by moving beyond the low-compliance standard of CPAP therapy. Its key achievement is the development and regulatory approval of the innovative Genio® neurostimulation system, which features a unique leadless, battery-free design activated by an external patch. The company's strategy is to drive global commercialization of Genio®, expand its clinical evidence base, and pursue label expansions to treat a broader patient population, positioning itself as a leader in the OSA neurostimulation market.
View full company profile